Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Exclusion Criteria

• •Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy; note: patients with recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube will be allowed, if the investigator believes the study treatment is a better alternative to initiation platinum-based chemotherapy, such as patients with a prior platinum allergy or low volume disease for whom platinum-based therapy is deferred until a later date
• •More than 4 prior chemotherapy regimens; note: repeat use of regimens count as 1 prior regimen; switching front-line therapy regimens (for example, from intraperitoneal to intravenous therapy) for reasons other than progression will count as 1 prior therapy; bevacizumab and other 'targeted' agents will count in the total number of prior regimens; vaccine therapies will not count in the total of prior therapies
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Any of the following prior therapies:
• •* Chemotherapy =\< 28 days prior to registration
• •* Mitomycin C/nitrosoureas =\< 42 days prior to registration
• •* Immunotherapy =\< 28 days prior to registration
• •* Biologic therapy =\< 28 days prior to registration
• •* Radiation therapy =\< 28 days prior to registration
• •* Investigational therapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration \[FDA\] approved indication and in the context of a research investigation) =\< 28 days prior to registration
• •* Prior poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) inhibitor therapy
• •Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment
• •Significant cardiovascular disease defined as congestive heart failure (New York Heart Association class III or IV cardiac disease), angina pectoris requiring nitrate therapy or recent myocardial infarction (=\< 6 months prior to registration)
• •Metastatic disease outside the intraperitoneal cavity and retroperitoneum, intrahepatic lesions, or pleural effusions; significant ascites precluding catheter placement; exception: intrahepatic lesions removed or planning to be removed during the debulking procedure
• •Any of the following:
• •* Nursing women
• •* Pregnant women
• •* Women of childbearing potential who are unwilling to employ adequate contraception (non-barrier method)
• •Immunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count \> 400 and do not require antiretroviral therapy
• •Receiving any other investigational agent that would be considered a treatment for the primary neoplasm
• •Other active malignancy =\< 1 year prior to registration
• •* EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
• •* NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer